What are the drug interactions and management considerations for a patient taking terbinafine, fluconazole, fluoxetine, lithium, lorazepam, and quetiapine?

Critical Drug Interactions Requiring Immediate Management

This polypharmacy regimen contains multiple serious drug interactions that require urgent medication review and dose adjustments, particularly the terbinafine-fluoxetine, fluconazole-quetiapine, and terbinafine-quetiapine combinations.

High-Priority Interactions

Terbinafine + Fluoxetine (CRITICAL)

Terbinafine is a potent CYP2D6 inhibitor that will significantly increase fluoxetine levels, risking serotonin syndrome and cardiac toxicity 1, 2. This combination creates:

• Serotonin syndrome risk: Mental status changes, neuromuscular hyperactivity (tremors, clonus), autonomic instability (hypertension, tachycardia, diaphoresis) 3
• Prolonged interaction: Terbinafine's CYP2D6 inhibition persists for months after discontinuation due to irreversible enzyme binding 4
• Management: Reduce fluoxetine dose by 50% immediately. Monitor closely for serotonin syndrome symptoms. Consider alternative antifungal (fluconazole has minimal CYP2D6 effects) 2, 5

Fluconazole + Quetiapine (HIGH RISK)

Fluconazole moderately inhibits CYP3A4, increasing quetiapine levels and QT prolongation risk 6, 7. Combined effects include:

• QT prolongation: Both drugs independently prolong QT interval; additive cardiotoxicity risk 6, 8
• Increased quetiapine exposure: Expect 30-50% increase in quetiapine levels 9
• Management: Reduce quetiapine dose by 30-50% during fluconazole therapy. Obtain baseline and follow-up ECG. Monitor for excessive sedation, orthostatic hypotension 7

Terbinafine + Quetiapine (MODERATE)

While not directly metabolized by CYP2D6, quetiapine levels may be affected through secondary pathways 9, 10. The combination clarithromycin-quetiapine showed elevated mortality (HR: 1.7) in large cohort studies 10, suggesting caution with all CYP3A4 inhibitors.

Moderate-Risk Interactions

Fluoxetine + Quetiapine

Fluoxetine increases quetiapine Cmax by 26% and AUC by 12% 11. This interaction is:

• Clinically manageable: The increase is statistically but not clinically significant in most patients 11
• Monitor for: Increased sedation, orthostatic hypotension, anticholinergic effects
• No dose adjustment typically needed unless patient experiences adverse effects 11

Lithium Considerations

Lithium has narrow therapeutic index; multiple interactions possible:

• Fluconazole: May increase lithium levels through renal effects (not well-documented but theoretically possible)
• Lorazepam: No direct pharmacokinetic interaction, but additive CNS depression 12
• Monitor: Lithium levels every 2-4 weeks during antifungal therapy, watch for lithium toxicity (tremor, confusion, ataxia)

Lorazepam + Quetiapine

Additive CNS depression and fall risk 12, 13:

• Both are CNS depressants with sedation, cognitive impairment, and fall risk
• Avoid concurrent use of ≥3 CNS agents when possible 13
• Consider tapering lorazepam if clinically appropriate 12

Antifungal Selection Strategy

If Treating Dermatophyte Onychomycosis:

Terbinafine is first-line but creates multiple interactions here 14:

1. Option 1: Switch to itraconazole pulse therapy (400 mg/day for 1 week/month × 2-3 pulses) 14

   • Avoids CYP2D6 inhibition
   • Still inhibits CYP3A4 (will increase quetiapine levels—reduce quetiapine dose by 50%)
   • Monitor liver function tests 14

2. Option 2: Continue terbinafine BUT:

   • Reduce fluoxetine dose by 50%
   • Monitor for serotonin syndrome weekly for first month
   • Warn patient interaction persists 3-6 months after stopping terbinafine 4

If Treating Candida Onychomycosis:

Fluconazole or itraconazole are preferred 14:

• Both require quetiapine dose reduction (30-50%)
• Fluconazole: 150-450 mg weekly × 3-6 months 14
• Monitor QT interval with ECG 6

Monitoring Protocol

Week 1-4 (Critical Period):

• Vital signs including orthostatic blood pressure
• Mental status assessment for serotonin syndrome
• ECG if using fluconazole + quetiapine
• Lithium level at week 2

Monthly:

• Liver function tests (all antifungals) 14
• Lithium levels
• Assessment for mood changes, sedation, falls

After Antifungal Completion:

• If used terbinafine: Continue monitoring for 3-6 months due to prolonged CYP2D6 inhibition 4
• May need to increase fluoxetine back to original dose gradually

Critical Warnings

Do NOT combine 3, 6:

• Any additional serotonergic agents (tramadol, dextromethorphan, St. John's wort)
• Additional QT-prolonging drugs (macrolides, ondansetron)
• MAOIs (contraindicated with fluoxetine)

Common pitfall: Assuming drug interactions resolve immediately after stopping terbinafine—the CYP2D6 inhibition persists for months and requires continued dose adjustments 4.